BridgeBio Pharma (NASDAQ:BBIO) is preparing to release its quarterly earnings on Tuesday, 2026-02-24. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect BridgeBio Pharma to report an earnings per share (EPS) of $-0.67.

Anticipation surrounds BridgeBio Pharma's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

Overview of Past Earnings

Last quarter the company missed EPS by $0.13, which was followed by a 4.88% drop in the share price the next day.

Here's a look at BridgeBio Pharma's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.82	-0.68	-1.00	-1.09
EPS Actual	-0.95	-0.95	-0.88	-1.40
Price Change %	-5.00	-9.00	5.00	0.00

BridgeBio Pharma Share Price Analysis

Shares of BridgeBio Pharma were trading at $68.14 as of February 20. Over the last 52-week period, shares are up 100.0%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for BridgeBio Pharma visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.